Bc. Vladyslav Mazhara

Laborant

Publikace

EXPERT OPINION ON INVESTIGATIONAL DRUGS. 2026;

SOT201: cis-acting PD-1/IL-15 mutein-based immunocytokine under investigational study in solid tumors

Journal for ImmunoTherapy of Cancer. 2025; 13(4); 10.1136/jitc-2024-010736

Novel PD-1-targeted; activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v

Journal for ImmunoTherapy of Cancer. 2025; 13(8); e010465

Temporal optimization of CD25-biased IL-2 agonists and immune checkpoint blockade leads to synergistic anticancer activity despite robust regulatory T cell expansion